You are currently viewing a new version of our website. To view the old version click .

Cancers, Volume 13, Issue 24

December-2 2021 - 242 articles

Cover Story: Melanoma is the least common but deadliest type of skin cancer. It is driven by mutations and epigenetic alterations in oncogenes and tumor suppressor genes. Epigenetic alterations lead to immune evasion and resistance to therapies. Melanoma treatments include surgery, targeted therapies and immune checkpoint blockade (ICB), which improve the survival of a small subset of patients. Thus, there is an urgent need to identify alternative combination therapies. Due to the susceptibility to extrinsic factors and reversible nature of melanoma, epigenetic drugs are investigated as a therapeutic avenue and as adjuvants for targeted therapies and ICB. Preclinical and clinical research studies on epigenetic drugs, such as HDAC and DNMT inhibitors, have shown the mechanisms by which these drugs can prevent resistance or enhance the therapeutic efficacy of current treatments for melanoma patients. View this paper
  • Issues are regarded as officially published after their release is announced to the table of contents alert mailing list .
  • You may sign up for email alerts to receive table of contents of newly released issues.
  • PDF is the official format for papers published in both, html and pdf forms. To view the papers in pdf format, click on the "PDF Full-text" link, and use the free Adobe Reader to open them.

Articles (242)

  • Article
  • Open Access
16 Citations
3,532 Views
11 Pages

Beneficial Prognostic Effects of Aspirin in Patients Receiving Sorafenib for Hepatocellular Carcinoma: A Tale of Multiple Confounders

  • Luca Ielasi,
  • Francesco Tovoli,
  • Matteo Tonnini,
  • Raffaella Tortora,
  • Giulia Magini,
  • Rodolfo Sacco,
  • Tiziana Pressiani,
  • Franco Trevisani,
  • Vito Sansone and
  • Giovanni Marasco
  • + 2 authors

20 December 2021

Case–control observational studies suggested that aspirin might prevent hepatocellular carcinoma (HCC) in high-risk patients, even if randomized clinical trials are lacking. Information regarding aspirin in subjects who already developed HCC, e...

  • Article
  • Open Access
11 Citations
5,402 Views
27 Pages

Anticancer Activity of Ω-6 Fatty Acids through Increased 4-HNE in Breast Cancer Cells

  • Chhanda Bose,
  • Ashly Hindle,
  • Jihyun Lee,
  • Jonathan Kopel,
  • Sahil Tonk,
  • Philip T. Palade,
  • Sharad S. Singhal,
  • Sanjay Awasthi and
  • Sharda P. Singh

20 December 2021

Her2-amplified breast cancers resistant to available Her2-targeted therapeutics continue to be a challenge in breast cancer therapy. Dox is the mainstay of chemotherapy of all types of breast cancer, but its usefulness is limited by cumulative cardio...

  • Article
  • Open Access
4 Citations
3,406 Views
10 Pages

Identification of Lynch Syndrome Carriers among Patients with Small Bowel Adenocarcinoma

  • Ariadna Sánchez,
  • Luis Bujanda,
  • Miriam Cuatrecasas,
  • Alex Bofill,
  • Cristina Alvarez-Urturi,
  • Goretti Hernandez,
  • Lara Aguilera,
  • Sabela Carballal,
  • Joan Llach and
  • Cristina Herrera-Pariente
  • + 11 authors

20 December 2021

Background: Small bowel adenocarcinoma (SBA) is a rare disease which can be associated with Lynch syndrome (LS). LS tumors are characterized by the presence of microsatellite instability (MSI) and/or the loss of mismatch repair (MMR) protein expressi...

  • Article
  • Open Access
30 Citations
3,190 Views
13 Pages

A Multidisciplinary Diagnostic Approach Reveals a Higher Prevalence of Indolent Systemic Mastocytosis: 15-Years’ Experience of the GISM Network

  • Roberta Zanotti,
  • Massimiliano Bonifacio,
  • Cecilia Isolan,
  • Ilaria Tanasi,
  • Lara Crosera,
  • Francesco Olivieri,
  • Giovanni Orsolini,
  • Donatella Schena and
  • Patrizia Bonadonna

20 December 2021

Systemic mastocytosis (SM) and other adult clonal mast cell disorders (CMD) are often underestimated, and their epidemiology data are scarce. We aimed at evaluating the impact of the activity of the Interdisciplinary Group for Study of Mastocytosis (...

  • Article
  • Open Access
8 Citations
3,092 Views
15 Pages

20 December 2021

Background: The incidence of lung cancer differs between men and women, suggesting the potential role of sex-specific influences in susceptibility to this cancer. While behavioural differences may account for some of the risk, another possibility is...

  • Article
  • Open Access
8 Citations
3,558 Views
15 Pages

20 December 2021

Apart from palliative chemotherapy, no other therapy has been proven effective for the treatment of locally advanced pancreatic tumors. In this study, an intraoperative high-intensity focused ultrasound (HIFU) device was tested in vivo to demonstrate...

  • Hypothesis
  • Open Access
13 Citations
3,748 Views
19 Pages

hsa_circ_0001275 Is One of a Number of circRNAs Dysregulated in Enzalutamide Resistant Prostate Cancer and Confers Enzalutamide Resistance In Vitro

  • Marvin C. J. Lim,
  • Anne-Marie Baird,
  • John Greene,
  • Ciara McNevin,
  • Karine Ronan,
  • Petar Podlesniy,
  • Orla Sheils,
  • Steven G. Gray,
  • Ray S. McDermott and
  • Stephen P. Finn

20 December 2021

Background: Enzalutamide is part of the treatment regimen for metastatic castration-resistant prostate cancer (MCRPC). However, both intrinsic and acquired resistance to the drug remain substantial clinical quandaries. circRNAs, a novel type of non-c...

  • Review
  • Open Access
36 Citations
9,238 Views
34 Pages

PARP Inhibitors and Myeloid Neoplasms: A Double-Edged Sword

  • Clifford M. Csizmar,
  • Antoine N. Saliba,
  • Elizabeth M. Swisher and
  • Scott H. Kaufmann

20 December 2021

Despite recent discoveries and therapeutic advances in aggressive myeloid neoplasms, there remains a pressing need for improved therapies. For instance, in acute myeloid leukemia (AML), while most patients achieve a complete remission with convention...

  • Article
  • Open Access
37 Citations
6,495 Views
32 Pages

Artificial Neural Networks Predicted the Overall Survival and Molecular Subtypes of Diffuse Large B-Cell Lymphoma Using a Pancancer Immune-Oncology Panel

  • Joaquim Carreras,
  • Shinichiro Hiraiwa,
  • Yara Yukie Kikuti,
  • Masashi Miyaoka,
  • Sakura Tomita,
  • Haruka Ikoma,
  • Atsushi Ito,
  • Yusuke Kondo,
  • Giovanna Roncador and
  • Juan F. Garcia
  • + 3 authors

20 December 2021

Diffuse large B-cell lymphoma (DLBCL) is one of the most frequent subtypes of non-Hodgkin lymphomas. We used artificial neural networks (multilayer perceptron and radial basis function), machine learning, and conventional bioinformatics to predict th...

  • Article
  • Open Access
4 Citations
3,350 Views
12 Pages

20 December 2021

Acute kidney injury (AKI) complicates the dosing strategies of oxaliplatin (L-OHP) and the requirement for L-OHP dose reduction in patients with renal failure remains controversial. The objective of this study is to assess the impact of AKI on the ph...

of 25

Get Alerted

Add your email address to receive forthcoming issues of this journal.

XFacebookLinkedIn
Cancers - ISSN 2072-6694